Cubist gains broader fast-track status for antibiotic

05/8/2013 | Boston Herald

The FDA has widened the fast-track status for Cubist Pharmaceuticals' CXA-201 drug to include hospital-acquired bacterial pneumonia and complicated urinary tract infections. The therapy targets pathogens including multidrug resistant Pseudomonas aeruginosa.

View Full Article in:

Boston Herald

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY